Compound hub · IGF-1 LR3
Is IGF-1 LR3 legal in Australia? Poisons Standard, TGA and WADA records
The records checked on 16 October 2026 give no simple yes or no. The October 2026 Poisons Standard (F2026L01327) has no entry naming IGF-1 LR3, and whether its group entry for insulin-like growth factors covers IGF-1 LR3 is not established. The TGA advisory of 13 April 2026 does not name IGF-1 LR3. The WADA 2026 Prohibited List covers IGF-1 and its analogues at S2.3.
01Short answerContents
IGF-1 LR3 faces three rulebooks in Australia. A national list of medicines and poisons keeps one record. A medicines regulator keeps another. A sports anti-doping agency keeps a third. Each answers its own question. The same molecule can appear in one record and not in another.
This page belongs to the IGF-1 LR3 hub. It sets out what each Australian and sport record says about IGF-1 LR3 and the date we checked it. That keeps three questions apart. Is it listed? Is it approved? Is it banned in sport?
Key facts
| Common name | IGF-1 LR3 |
|---|---|
| Poisons Standard | No individual entry; class entry INSULIN-LIKE GROWTH FACTORS in Schedule 4 and Appendix D, clause 5; reach not established (F2026L01327, checked 16 October 2026) |
| ARTG | Mecasermin product Increlex is entry 308494; no registered IGF-1 LR3 product confirmed |
| TGA advisory | 13 April 2026 names five other compounds, not IGF-1 LR3 |
| WADA 2026 Prohibited List | S2.3 names IGF-1 (mecasermin) and its analogues; prohibited at all times; in force from 1 January 2026 (WADA 2026 List) |
| Records checked | 16 October 2026 |
Is IGF-1 LR3 legal in Australia?
The records give no simple answer. The Poisons Standard is the national list that sorts medicines and poisons into groups called schedules. It has no entry that names IGF-1 LR3. It does have a group entry, INSULIN-LIKE GROWTH FACTORS, in Schedule 4 and in Appendix D, clause 5. Whether that group entry covers this analogue is not settled. We checked the October 2026 version of the list (F2026L01327) on 16 October 2026. That check does not support saying IGF-1 LR3 is Schedule 4. It also does not support saying IGF-1 LR3 is unscheduled.
To answer the question, a lawyer must read the current list and the Therapeutic Goods Act 1989. The Australian peptide law guide explains the layers. The TGA notes that state and territory laws may add more controls.

Is IGF-1 LR3 in the Poisons Standard?
IGF-1 LR3 is not named on its own in the October 2026 Poisons Standard. The list, dated 28 September 2026, has two related entries in Schedule 4. One is INSULIN-LIKE GROWTH FACTOR I. The other is INSULIN-LIKE GROWTH FACTORS, except when separately specified in this Schedule. The list also names INSULIN-LIKE GROWTH FACTORS in Appendix D, clause 5. A text search found neither LR3 nor Long R3. Whether the group entry or the rules on derivatives cover this analogue is a legal question. This page does not answer it. A missing name does not mean a substance is unscheduled.
Schedule 4 is the group for prescription-only medicines. What Schedule 4 and Appendix D mean explains both. A missing name is not permission. Group headings and rules on derivatives can cover things that are not named. A derivative is a substance made from a listed one. The check is narrow. It finds named entries and nothing more.
Mecasermin, the approved IGF-1 medicine, is a separate matter. The entry for insulin-like growth factor I covers the human hormone. That entry does not decide the status of the analogue.
Is IGF-1 LR3 on the ARTG, and has the TGA issued a warning?
The TGA records checked do not confirm that any IGF-1 LR3 product is registered. The TGA's peptide advisory is a public notice dated 13 April 2026. It does not name IGF-1 LR3. The ARTG is the national register of medicines and other health products. It lists the mecasermin product Increlex as entry 308494. Its sponsor is Asteri Pharma Pty Ltd, and it was registered on 22 November 2019. That record is for mecasermin. It does not approve IGF-1 LR3. We did not search the whole register. So these records cannot prove that no related registration exists.
The advisory says the TGA has not assessed unapproved peptide products for safety, quality or effectiveness. It gives BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples. It also says a research-use-only label alone does not make supply lawful (TGA advisory, 13 April 2026). It adds that state and territory laws may set more controls on the sale, supply and possession of unapproved peptide products.
The TGA topic page Peptide products, was last updated on 23 September 2026. We read it on 16 October 2026. It does not name IGF-1 LR3 either. Anyone can search the register on the TGA's ARTG page.
Is IGF-1 LR3 banned in sport?
The WADA 2026 Prohibited List came into force on 1 January 2026. WADA is the World Anti-Doping Agency. Under S2.3, Growth Factors and Growth Factor Modulators, the list bans insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues at all times, in and out of competition. The list does not print the letters LR3. IGF-1 LR3 is an analogue of IGF-1, so the analogue wording is read to cover it. That reading comes from the list text. It does not decide any single athlete's case.
The list marks every substance in class S2 as a non-Specified Substance. WADA publishes a new list each year. A later list may differ from the 2026 text quoted here. Sport rules are separate from the Poisons Standard and from TGA approval. The guide to peptides and drug tests covers how testing relates to the list.
Anti-doping labs have published ways to detect the analogue. A 2021 study checked a method for LongR3-IGF-I, Des(1-3)-IGF-I and R3-IGF-I. The method first pulls the molecules out with antibodies. Then it identifies them with high-resolution mass spectrometry. The team tested it in rats. The authors describe the three analogues as banned in sport and never approved for use in humans. This is a lab and rat result. It does not state any person's status.
Evidence limits
What do these records not settle?
These records do not settle whether a particular person may lawfully supply, import or possess IGF-1 LR3 in Australia. The Poisons Standard contains named substances, group entries and rules on derivatives. The TGA advisory deals with unapproved peptide products as a group. It notes that state and territory laws may add controls. WADA deals only with sport. A medicine registration, a schedule entry and an anti-doping rule each answer a different question. Putting them together does not create a legal answer for one person. This page records the sources. It leaves open what they have not settled.
A missing approval, a group entry and a seller's label are three different facts. The research-use-only wording on a vial is the seller's statement of intent. The TGA has said that such wording alone does not change a product's regulatory status (TGA advisory, 13 April 2026). The Western Australian law guide sets out the Western Australian layer.
Comparison
Four records checked for IGF-1 LR3, each read on 16 October 2026. 'What it does not say' lists what the record leaves open. Records only; this is not legal advice.
| Body | Record and date | What it says about IGF-1 LR3 | What it does not say |
|---|---|---|---|
| Poisons Standard (Commonwealth) | F2026L01327, dated 28 September 2026 | No entry naming it; group entry INSULIN-LIKE GROWTH FACTORS in Schedule 4 and Appendix D, clause 5 | Whether the group entry covers IGF-1 LR3 |
| TGA, ARTG | ARTG 308494, registered 22 November 2019 | Lists mecasermin as Increlex; no IGF-1 LR3 product confirmed | That no IGF-1 LR3 product is registered, because a name search does not prove absence |
| TGA, advisory | Advisory, 13 April 2026 | Treats unapproved peptide products as a group and does not name IGF-1 LR3 | The status of any specific product |
| WADA | 2026 Prohibited List, S2.3 | Names IGF-1 (mecasermin) and its analogues; banned at all times | The letters LR3, or an athlete's individual status |
FAQ
Is IGF-1 LR3 a Schedule 4 substance?
Not established. The Poisons Standard has no entry naming it. A Schedule 4 group entry for insulin-like growth factors may or may not cover the analogue. We checked the October 2026 list on 16 October 2026. A flat statement either way would go beyond the record.
Is IGF-1 LR3 on the ARTG?
No registered IGF-1 LR3 product was confirmed on 16 October 2026. The ARTG does list the mecasermin product Increlex as entry 308494, and that listing does not cover IGF-1 LR3.
Is IGF-1 LR3 banned by WADA?
The WADA 2026 Prohibited List bans IGF-1 and its analogues at S2.3, at all times. IGF-1 LR3 is an analogue of IGF-1, so the wording is read to cover it. The list does not print LR3.
Does a research-use-only label change the legal status?
The TGA states that research-use-only labels alone do not change a product's regulatory status. They do not permit importing the product. They do not remove advertising or supply duties.
Is mecasermin legal in Australia?
Mecasermin is an approved medicine. The ARTG lists Increlex as entry 308494. That listing applies to that product. It does not approve IGF-1 LR3.
More in this hub
Citations
1 sourcesMongongu C, Coudoré F, Domergue V, et al. Drug Testing and Analysis. 2021;13(7):1256-1269.
doi:10.1002/dta.3016
Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
